openPR Logo
Press release

Recurrent Glioblastoma Multiforme (GBM) Treatment Market Report to 2016- 2022: By Treatment type, End User, by Geography and Company Profile

12-20-2017 09:21 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Persistence Market Research

/ PR Agency: Persistence Market Research
Recurrent Glioblastoma Multiforme (GBM) Treatment Market

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above.

View Report Preview:
https://www.persistencemarketresearch.com/market-research/recurrent-glioblastoma-multiforme-gbm-treatment-market.asp

Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.

Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then treating with chemotherapy and radiation. While this treatment plan is the currently accepted standard of care, it does not effectively prevent tumor recurrence, which ultimately causes death in GBM patients. This factor is expected to be the prime restraint for the growth of recurrent glioblastoma multiforme market.

Recurrent Glioblastoma Multiforme (GBM) market is segmented on the basis of treatment, end user and geography.

Based on treatment, GBM market can be segmented as follows:

Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation therapy
Chemotherapy

Based on end user, GBM market can be segmented as follows:

Hospitals
Clinics
Ambulatory surgical centers

Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for patients with unfavorable low-grade glioma to improve progression free survival. The most frequently used chemotherapy regimens are a combination of procarbazine, lomustine and vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM treatment market to a great extent.

Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominates the global GBM market owing to rising awareness, population aging, changing lifestyle and increasing healthcare awareness accentuates the growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an emerging market due to increasing demand for better healthcare facilities.

Request to view Sample Report:
https://www.persistencemarketresearch.com/samples/10112

Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.

About Us

Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact Us

Persistence Market Research

305 Broadway,7th Floor
New York City, NY 10007
United States
T: +1-646-568-7751
Tollfree: +1 800-961-0353
Email: sales@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recurrent Glioblastoma Multiforme (GBM) Treatment Market Report to 2016- 2022: By Treatment type, End User, by Geography and Company Profile here

News-ID: 869026 • Views:

More Releases from Persistence Market Research

Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Reaching USD 82.4 Billion by 2031
Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Re …
The Artificial Intelligence as a Service (AIaaS) market has emerged as one of the most transformative segments in the global technology ecosystem. By providing AI capabilities on a subscription or pay-per-use model, AIaaS allows organizations to deploy advanced AI functionalities without the need for significant in-house infrastructure. This model has democratized access to AI, enabling small and medium-sized enterprises to leverage predictive analytics, natural language processing, and machine learning tools
Server Operating System Market Anticipated to Witness Robust Growth, Reaching USD 34.5 Billion by 2031
Server Operating System Market Anticipated to Witness Robust Growth, Reaching US …
The server operating system market is witnessing robust growth, driven by the rapid expansion of data centers and the surging adoption of cloud technologies across enterprises worldwide. Server operating systems form the backbone of modern IT infrastructure, enabling organizations to efficiently manage hardware resources, deploy applications, and maintain high levels of system reliability and security. As businesses increasingly migrate to cloud environments and data-intensive operations grow, demand for powerful, scalable,
Manufacturing Operations Management Software Industry Anticipated to Witness Rapid Growth, Reaching USD 69.8 Billion by 2032
Manufacturing Operations Management Software Industry Anticipated to Witness Rap …
The Manufacturing Operations Management (MOM) software market is rapidly emerging as a cornerstone of digital transformation in the manufacturing sector. As industries increasingly adopt Industry 4.0 practices, the need for advanced solutions that integrate production planning, real-time monitoring, quality control, and process optimization has surged. MOM software enables manufacturers to streamline operations, reduce production downtime, and improve overall efficiency, making it an indispensable tool across automotive, pharmaceutical, aerospace, and consumer
G.Fast Chipset Market Forecast to Expand with Absolute $ Growth of USD 28.3 Billion by 2032
G.Fast Chipset Market Forecast to Expand with Absolute $ Growth of USD 28.3 Bill …
The G.Fast chipset market has emerged as a pivotal segment within the broadband and telecommunication infrastructure industry, driven by the rising demand for high-speed internet and improved last-mile connectivity solutions. With advancements in fiber-to-the-distribution-point (FTTdp) networks, the adoption of G.Fast chipsets has witnessed unprecedented growth across residential, commercial, and industrial applications. These chipsets enable ultra-fast broadband speeds over existing copper lines, bridging the performance gap between fiber and legacy infrastructures,

All 5 Releases


More Releases for GBM

Glioblastoma Multiforme (GBM) Treatment Market Report 2024: Trends and Projectio …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $3.66 billion In
Goodpasture Syndrome (Anti-GBM Disease) With Excellent CAGR 5.30%
Goodpasture Syndrome Treatment market analysis report is a professional and a detailed market study focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. This market report is a comprehensive background analysis of the ABC industry, which includes an assessment of the parental market. The report also aids in prioritizing market goals and attain profitable business. This analysis gives an examination of various segments that are relied
Anti-GBM Autoantibody Disease Market - Embracing Immune Harmony: Anti-GBM Autoan …
Newark, New Castle, USA - new report, titled Anti-GBM Autoantibody Disease Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-GBM Autoantibody Disease market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-GBM Autoantibody Disease market. The report offers an overview of
Glioblastoma Multiforme Treatment (GBM) Market: Trends, Opportunities & Regional …
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is